Home' Australian Pharmacist : Australian Pharmacist August 2015 Contents Australian Pharmacist August 2015 I © Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month
(15,500 pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than
10,000 pharmacists – a typical monthly article receives 3000 plus
assessments, with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 69.
Across: 2. Mites, 5. Intranasal, 6. Dust,
11. Rhinorrhoea, 12. Rhinitis, 13. Saliva,
Down: 1. Corticosteroid, 2. Mould,
3. Congestion, 4. Antihistamine,
7. Sublingual, 8. Hayfever, 9. Dander,
Lucentis (ranibizumab) was PBS listed on
1 July for patients experiencing vision
loss caused by either diabetic macula
oedema (DME) or macular oedema
secondary to branch or central retinal
vein occlusion (BRVO and CRVO).
Professor Paul Mitchell, Head of
Ophthalmology at Sydney’s Westmead
Hospital said: ’We have known for
some time that intravitreal therapy can
improve visual acuity in people with
DME2 and BRVO/CRVO2,3
a subsidy medicines like Lucentis have
been out of reach for most patients.
This subsidy has the potential to
increase the number of patients who
receive treatment for DME, BRVO
Lucentis belongs to a class of medicines
known as anti-vascular endothelial
growth factor (VEGF). It works by
preventing damaged or blocked
blood vessels from leaking fluid
into the macula4; thereby reducing
swelling, which if left untreated can
have a detrimental impact on sharp,
Lucentis is contraindicated in patients
with hypersensitivity to the product
and its components, intraocular
and periocular inflammation and
It may cause transient
increases in intraocular pressure,
and inflammation of the eye.
The efficacy and tolerability profiles of
Lucentis for the treatment of DME, BRVO
and CRVO have been demonstrated
through a comprehensive clinical
1. Mitchell P et al. The RESTORE Study: Ranibizumab
Monotherapy or Combined with Laser versus Laser
Monotherapy for Diabetic Macular Edema. Opthalmology.
2. Brown D et al. Sustained Benefits from Ranibizumab for
Macular Edema Following Branch Retinal Vein Occlusion:
12-Month Outcomes of a Phase III Study. Opthalmology.
3. Campochiaro P et al. Sustained Benefits from Ranibizumab
for Macular Edema following Central Retinal Vein
Occlusion: Twelve-Month Outcomes of a Phase III Study.
4. Novartis. Lucentis Consumer Medicine Information. At:
5. Novartis. Lucentis Australian Product Information, 2015.
Links Archive Australian Pharmacist July 2015 Australian Pharmacist September 2015 Navigation Previous Page Next Page